

**Washington State Pharmacy and Therapeutics Committee / Drug Utilization Review Board**  
**Meeting by Zoom Webinar**  
**Wednesday, June 15, 2022 9 a.m. to 4 p.m.**

Agenda		
Time	Topic	Presenter
9 a.m.	<b>Welcome &amp; Introductions</b>  <b>Pharmacy &amp; Therapeutics (P&amp;T) Committee Convenes (Reviews drug classes for the WA PDL)</b>	Jordan Storhaug, Committee Chair
9:05 a.m.	<b>TIMs for Plaque Psoriasis and Psoriatic Arthritis- report</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Leila Kahwati, DERP
10 a.m.	<b>TIMs for Rheumatoid Arthritis and Ankylosing Spondylitis</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Gerald Gartlehner, DERP
11 a.m.	<b>Break (10 min)</b>	<b>All</b>
11:10 a.m.	<b>Second generation antipsychotics in children- surveillance</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Beth Shaw, DERP
11:35 a.m.	<b>Newer Diabetes- surveillance</b> <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Beth Shaw, DERP
12 p.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns</b>	Jordan Storhaug, Committee Chair
12 p.m.	<b>Lunch (30 min)</b>	All
12:30 p.m.	<b>P&amp;T Committee and DUR Board process overview</b>	Donna Sullivan, HCA
12:50 p.m.	<b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>	Jordan Storhaug, Committee Chair
12:50 p.m.	<b>Asthma and COPD Agents</b> <ul style="list-style-type: none"> <li>• Anticholinergics</li> <li>• Phosphodiesterase 4 Inhibitors</li> <li>• Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations</li> <li>• Long Acting Muscarinic Agents               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
12:55 p.m.	<b>Asthma and COPD Agents</b> <ul style="list-style-type: none"> <li>• Inhaled Corticosteroid Combinations</li> <li>• Inhaled Corticosteroids               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

1:10 p.m.	<b>Asthma and COPD Agents</b> <ul style="list-style-type: none"> <li>• Monoclonal Antibodies <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
1:35 p.m.	<b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>• Gaucher Disease <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
1:40 p.m.	<b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>• Sickle Cell Anemia <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
2:00 p.m.	<b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>• Granulocyte Colony-Stimulating Factors (G-CSF) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
2:20 p.m.	<b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>• Erythropoiesis-Stimulating Agents (ESAS) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
2:25 p.m.	<b>Break (10 min)</b>	<b>All</b>
2:35 p.m.	<b>Immune Modulators</b> <ul style="list-style-type: none"> <li>• Thalidomide Analogues</li> </ul> <b>Oncology Agents</b> <ul style="list-style-type: none"> <li>• Alkylating Agents – Oral</li> <li>• Antimetabolites – Oral</li> <li>• Antineoplastics Misc – Oral</li> <li>• BCL-2 Inhibitors – Oral</li> <li>• Histone Deacetylase Inhibitors – Oral</li> <li>• Isocitrate Dehydrogenase-1 (IDH1) Inhibitors – Oral</li> <li>• Isocitrate Dehydrogenase-2 (IDH2) Inhibitors – Oral</li> <li>• Janus Associated Kinase (JAK) Inhibitors – Oral</li> <li>• Phosphatidylinositol 3-Kinase (PI3K) Inhibitors – Oral</li> <li>• Proteasome Inhibitors – Oral</li> <li>• XPO1 Inhibitors - Oral <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3:40 p.m.	<b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>• Thrombopoiesis (TPO) Stimulating Proteins <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3:45 p.m.	<b>Endocrine and Metabolic Agents</b> <ul style="list-style-type: none"> <li>• Growth Hormone Releasing Hormones (GHRH) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
3:50 p.m.	<b>Endocrine and Metabolic Agents</b> <ul style="list-style-type: none"> <li>• Growth Hormones <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

4:00 p.m.	• <b>DUR Board Adjourns</b>	Jordan Storhaug, Committee Chair
-----------	-----------------------------	-------------------------------------

*For all Apple Health (Medicaid) questions, please email [AppleHealthPolicy@hca.wa.gov](mailto:AppleHealthPolicy@hca.wa.gov)*

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.